Results
Halozyme Q1 Beats Estimates, Guidance Below Consensus
Halozyme posted Q1 adjusted EPS $1.60 beating estimate $1.54 and revenue $377M up 42% YoY, exceeding forecasts.
Royalty revenue rose 43% YoY to $240.7M, driven by ENHANZE partner products DARZALEX SC,
